Daily Bulletin

New data independently confirms and extends laboratory findings and expands safety profile of ATH434-PR Newswire APAC

  • Written by PR Newswire Asia - Daily Bulletin Au RSS
Cision

MELBOURNE, Australia and SAN FRANCISCO, Aug. 4, 2020 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") today announced that new clinical and experimental pharmacology data for its lead drug candidate ATH434 (formerly PBT434) has been selected for presentation at the 2020 International Congress of...

Read more: New data independently confirms and extends laboratory findings and expands safety profile of...

More Articles ...

  1. Tile™ and Skullcandy Create Most Advanced True Wireless Finding Experience-PR Newswire APAC
  2. Trade360 Announces New Trading Platform-PR Newswire APAC
  3. Alterity Releases Appendix 4C - Q4 FY20 Quarterly Cash Flow Report-PR Newswire APAC

Business News

A Guide to Finance Automation Software

When running a business, it is critical to streamline certain processes to maintain efficiency. Too much to spent manually on tasks can wind up being detrimental to the overall health of the organis...

Daily Bulletin - avatar Daily Bulletin

Top Tips for Cost-effective Storefront Signage

The retail industry is highly competitive and if you are in the process of setting up a retail store, you have come to the right place, as we offer a few tips to help you create a stunning storefront...

Daily Bulletin - avatar Daily Bulletin

How Freight Forwarding Simplifies Global Trade Operations

Global trade operations are becoming increasingly complex due to international regulations, customs procedures, and the sheer scale of global logistics. For businesses looking to expand internation...

Daily Bulletin - avatar Daily Bulletin